FIGURE 5

Inhibiting senescence decreases the behavioral disabilities of ppp2r2c‐compromised fish. Behavioral tests of WT and ppp2r2c ^m1/m1 with or without ABT263 treatment for 3 days, ppp2r2c ^m1/m1 p53 ^−/− and ppp2r2c ^m1/m1 cdkn1a ^−/− at 6 months old. (a) Representative result from locomotion activity upon light–dark transition assay during the 30‐s lights‐on period and 30 s before lights‐on. (b) Quantification of the highly active state duration during the 30‐s lights‐on period (n = 11 for ppp2r2c ^m1/m1 p53 ^−/− ; n = 10 for WT‐vehicle, ppp2r2c ^m1/m1 ‐vehicle and ppp2r2c ^m1/m1 cdkn1a ^−/− groups; n = 9 for WT‐ABT263; n = 8 for ppp2r2c ^m1/m1 ‐ABT263). (c) Representative movement tracks (gray lines) of WT and ppp2r2c ^m1/m1 with or without ABT263 treatment for 3 days, ppp2r2c ^m1/m1 p53 ^−/− and ppp2r2c ^m1/m1 cdkn1a ^−/− in the mirror image attack assay. Blue boxes show the position of the mirror. (d) Quantification of the number of mirror attacks in 5‐min intervals (n = 11 for ppp2r2c ^m1/m1 p53 ^−/− ; n = 10 for WT‐vehicle, ppp2r2c ^m1/m1 ‐vehiclem and ppp2r2c ^m1/m1 cdkn1a ^−/− groups; n = 9 for WT‐ABT263 and ppp2r2c ^m1/m1 ‐ABT263). (e) Representative movement tracks (gray lines) of WT and ppp2r2c ^m1/m1 with or without ABT263 treatment for 3 days, ppp2r2c ^m1/m1 p53 ^−/− and ppp2r2c ^m1/m1 cdkn1a ^−/− during a 30‐min trial in the open field test. The red box shows the central area of the tank. (f) Quantification of the cumulative time that fish stayed within the central area (n = 10 for WT‐vehicle, ppp2r2c ^m1/m1 ‐vehicle, and ppp2r2c ^m1/m1 cdkn1a ^−/− groups; n = 9 for WT‐ABT263, ppp2r2c ^m1/m1 ‐ABT263, and ppp2r2c ^m1/m1 p53 ^−/− ). Data are means ± SEM. **p < 0.01; one‐way ANOVA